January 2012
The biotech sector performed strongly during the month mainly due to M&A activity and strong product launches. Dendreon and Gilead were the top contributors to performance, Dendreon reported better than expected results and Gilead performed strongly after takeover of Pharmasset.
Read More…
Latest Fact Sheet
Latest Annual or Interim Report
At Close 22 Feb 2012
Price:228.00p
NAV:237.26p
Prem/-Disc:-3.90%
Source: Morningstar
Net Asset Value per ordinary share, including income, fully diluted.
To request emailed copies of monthly fact sheets and other relevant information, please register below.